Ekso Bionics Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Net Loss Per Share of Common Stock (Tables)

Net Loss Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2017

Schedule of Earnings Per Share, Basic and Diluted

Basic net loss per share of common stock is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed using the weighted average number of common stock, adjusted to include conversion of certain stock options and warrants for common stock and release of common stock in connection with restricted stock units during the period, as follows:

	Years ended December 31,
	2017		2016⁽¹⁾		2015
Numerator:

Net loss applicable to common stockholders	$	(29,122)	$	(33,815)	$	(24,245)
Adjustment for gain on fair value of warrant liability		-		(4,286)		(2,505)
Adjusted net loss used for dilution calculation	$	(29,122)	$	(38,101)	$	(26,750)

Denominator
Weighted-average number of shares outstanding		35,609		18,126		14,606
Effect of potential dilutive shares		-		496		3
Dilutive weighted-average number of shares outstanding		35,609		18,622		14,609

Net loss per share applicable to common stockholders
Basic	$	(0.82)	$	(1.87)	$	(1.66)
Diluted	$	(0.82)	$	(2.05)	$	(1.83)

⁽¹⁾

Recognition of previously deferred revenue and cost of goods in the year ended December 31, 2016 reduced net loss applicable to common stockholders by $2,358, or $0.13 per share (see Note 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates – Medical Device Revenue and Cost of Revenue Recognition).

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following potential dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive:

	Years ended December 31,
	2017		2016		2015
Options to purchase common stock		3,156		2,477		1,963
Restricted stock units		616		-		-
Warrants for common stock		3,396		1,963		1,963
Common stock issuable upon conversion of preferred shares		-		-		1,876
Total common stock equivalents		7,168		4,440		5,802